8028#Background:MRD assessment is a known surrogate marker for survival in multiple myeloma (MM). However, some patients with non-detectable MRD, do relapse, and some MRD-positive patients with an extensive follow-up, do not relapse. Clonal diversity is defined as the number of unique ...
[5]. Johnson, J. Janssen Announces DARZALEX® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible. 2018; Available from: https://www.jnj.com/media-center/press-relea...
MRD testing in multiple myeloma: the main future driver for modern tailored treatment. Semin Hematol. 2018;55:44–50. Article PubMed Google Scholar Berger N, Kim-Schulze S, Parekh S. Minimal residual disease in multiple myeloma: impact on response assessment, prognosis and tumor heterogeneity....
Natalie S. Callander, MD:We’ve had a huge debate on this institutionally. We’re doing it by consensus post-transplant. What we’re not doing is using a single result, like Pete says, to determine ending treatment unless somebody’s on a clinical trial. Patients are asking for it. Many...
FDA. FDAauthorizes first next generation sequencing-based test to detect very lowlevels of remaining cancer cells in patients with acute lymphoblastic leukemiaor multiple myeloma. 2018; Available from:https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-next-generation-sequencing-base...
[2] Valeria Ferla, Elena Antonini, Tommaso Perini, et al. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.Front Oncol. 2022 Aug 16;12:932852. doi: 10.3389/fonc.2022.932852. ...
[1] Paiva, B., van Dongen, J. J. M. & Orfao, A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 125, 3059–3068 (2015). [2] G M. et al. BCG in cancer immun...
MRD is very commonly used with blood cancers, such as leukemia, lymphoma, or multiple myeloma, as well as for other cancers such as lung cancer, colorectal cancer, and breast cancer. In cases of acute myeloid leukemia (AML), a positive MRD test generally results in a higher rate of diseas...
any technology is better than others for MRD-testing. With ‘next-generation flow cytometry’, MPFC is able to achieve a sensitivity of 2 × 10E–6 and is reportedly more accurate compared with NGS-based MRD-testing for predicting posttransplant PFS and survival in plasma cell myeloma [153]...
clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) test service to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leu...